| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -2,158,354 |
| Stock-based compensation | 237,644 |
| Amortization of loan commitment fee | 17,440 |
| Grant receivable | 63,393 |
| Prepaid expenses | -90,668 |
| Accounts payable | 383,364 |
| Accrued expenses | 92,769 |
| Net cash used in operating activities | -1,273,076 |
| Net decrease in cash | -1,273,076 |
| Cash and cash equivalents at beginning of period | 11,627,849 |
| Cash and cash equivalents at end of period | 10,354,773 |
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)